Abstract
Bone metastases are common in the event of malignancy and are inevitably associated with serious complications that may deteriorate the quality of life (QOL) of patients and threaten life. Both radiotherapy (RT) and bisphosphonates (BPs) have an established role in the management of metastatic bone disease. Many clinical trials have demonstrated their effectiveness when used as sole treatment modalities, but only a few have evaluated their therapeutic value when applied concomitantly. We herein discuss the pathophysiology of bone metastases and the potential interactions between RT and BPs. Moreover, the results of both animal models and clinical studies are presented in detail. Apart from aspects of normal tissue tolerance, other interactions include spatial cooperation and additive or super-additive effects. The latter brings about a synergistic activity that results in an enhanced reossification, improved bone stability and microarchitecture, and increased mechanical strength, as documented through animal model studies. The results of published clinical studies investigating the effectiveness of concomitant application of RT and BPs are promising, reporting a significant clinical and radiologic response. More specifically, a significant reduction of pain scores and a worth noticing improvement in QOL and performance status (PS) were noted, accompanied by a considerable increase in bone density. Pain relief was accompanied by a marked reduction in analgesic opioid need. The enhanced reossification may be responsible for the improved therapeutic response, since it was shown that the correlation between pain and bone density is negative and strong. Although promising and encouraging, the results of such studies should be corroborated by larger, randomized trials.
Keywords: Bisphosphonates, radiotherapy, bone metastases, bone density, pain, ibandronate, pamidronate, zoledronic acid
Anti-Cancer Agents in Medicinal Chemistry
Title: The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Volume: 9 Issue: 3
Author(s): V. Vassiliou and D. Kardamakis
Affiliation:
Keywords: Bisphosphonates, radiotherapy, bone metastases, bone density, pain, ibandronate, pamidronate, zoledronic acid
Abstract: Bone metastases are common in the event of malignancy and are inevitably associated with serious complications that may deteriorate the quality of life (QOL) of patients and threaten life. Both radiotherapy (RT) and bisphosphonates (BPs) have an established role in the management of metastatic bone disease. Many clinical trials have demonstrated their effectiveness when used as sole treatment modalities, but only a few have evaluated their therapeutic value when applied concomitantly. We herein discuss the pathophysiology of bone metastases and the potential interactions between RT and BPs. Moreover, the results of both animal models and clinical studies are presented in detail. Apart from aspects of normal tissue tolerance, other interactions include spatial cooperation and additive or super-additive effects. The latter brings about a synergistic activity that results in an enhanced reossification, improved bone stability and microarchitecture, and increased mechanical strength, as documented through animal model studies. The results of published clinical studies investigating the effectiveness of concomitant application of RT and BPs are promising, reporting a significant clinical and radiologic response. More specifically, a significant reduction of pain scores and a worth noticing improvement in QOL and performance status (PS) were noted, accompanied by a considerable increase in bone density. Pain relief was accompanied by a marked reduction in analgesic opioid need. The enhanced reossification may be responsible for the improved therapeutic response, since it was shown that the correlation between pain and bone density is negative and strong. Although promising and encouraging, the results of such studies should be corroborated by larger, randomized trials.
Export Options
About this article
Cite this article as:
Vassiliou V. and Kardamakis D., The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871520610909030326
DOI https://dx.doi.org/10.2174/1871520610909030326 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Targeting Neurite Growth Inhibitors to Induce CNS Regeneration
Current Pharmaceutical Design The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Formulation and Characterization of Mucoadhesive Microparticles of Cinnarizine Hydrochloride Using Supercritical Fluid Technique
Current Drug Delivery Pramipexole Responsive Neck Numbness: The Therapeutic Role of Dopamine Agonists in the Spinal Cord Indicating to a Common Spinal Pathophysiology with Restless Leg Syndrome (RLS)?
Current Clinical Pharmacology Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Current Drug Delivery Stem Cells in Skeletal Tissue Engineering: Technologies and Models
Current Stem Cell Research & Therapy Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?
Current Alzheimer Research Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Endocrine, Metabolic & Immune Disorders - Drug Targets Boron Nitride Nanotubes: Production, Properties, Biological Interactions and Potential Applications as Therapeutic Agents in Brain Diseases
Current Nanoscience Anticancer Activity of Bisphosphonates in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Recent Patents on Cell-based Approaches to Collagen Enrichment and Repair
Recent Patents on Regenerative Medicine Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Magnetic Nanoparticles: Properties, Synthesis and Biomedical Applications
Current Drug Metabolism An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued)